MARKET

ITCI

ITCI

Intra-Cellular Therapies
NASDAQ
68.55
-1.18
-1.69%
Opening 13:06 03/28 EDT
OPEN
69.78
PREV CLOSE
69.72
HIGH
70.00
LOW
68.14
VOLUME
359.22K
TURNOVER
0
52 WEEK HIGH
76.11
52 WEEK LOW
45.50
MARKET CAP
6.64B
P/E (TTM)
-47.0550
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ITCI last week (0318-0322)?
Weekly Report · 3d ago
Buy Rating Affirmed on Intra-Cellular Therapies Ahead of Key Phase 3 Results and Strategic Leadership Enhancements
TipRanks · 03/21 06:45
Intra-Cellular Therapies Announces Executive Leadership Changes
TipRanks · 03/19 13:02
Intra-Cellular Therapies promotes Michael Halstead to President
Intra-Cellular Therapies promotes Michael Halstead to the position of President. Halstead is currently serving as Executive Vice President and General Counsel. Senior Vice President Larry Hineline will be retiring after more than 20 years of service. Intra- cellular therapeutic, Inc. (ITCI)
Seeking Alpha · 03/19 12:43
Intra-Cellular Therapies Chief Financial Officer Larry Hineline to Retire
Intra-Cellular Therapies' long-time finance chief, Larry Hineline, is retiring after more than two decades with the company. Hineline has been chief financial officer since June 2002. The biopharmaceutical company has launched an external search for a successor.
Dow Jones · 03/19 12:43
*Intra-Cellular Therapies Initiated External Search for a New Chief Fincl Officer >ITCI
Dow Jones · 03/19 12:32
*Intra-Cellular Therapies: Hineline Has Agreed to Remain Through the Process to Ensure Smooth Transition >ITCI
Dow Jones · 03/19 12:32
*Intra-Cellular Therapies: Chief Fincl Officer Larry Hineline Will Be Retiring >ITCI
Dow Jones · 03/19 12:31
More
About ITCI
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.

Webull offers Intra-Cellular Therapies Inc stock information, including NASDAQ: ITCI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ITCI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ITCI stock methods without spending real money on the virtual paper trading platform.